OncoMatch/Head & Neck Cancer (HNSCC)/PD-L1 (CD274)
Head & Neck Cancer (HNSCC)PD-L1 (CD274) Clinical Trials
PD-L1 CPS ≥1 (pembrolizumab monotherapy) and CPS ≥20 (pembrolizumab monotherapy with strongest benefit) are the approved eligibility thresholds for first-line recurrent/metastatic HNSCC per KEYNOTE-048. Pembrolizumab plus chemotherapy is approved regardless of CPS. Trials investigate novel checkpoint combinations, anti-CTLA-4/LAG-3 regimens, and induction IO strategies in locally advanced CPS-stratified HNSCC.
Top recruiting PD-L1 (CD274) Head & Neck Cancer (HNSCC) trials
Ranked by phase and US site count. See all 61 trials matched to your profile →
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Bicara Therapeutics
A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
Merus B.V.
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
BioNTech SE
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases
Rakuten Medical, Inc.
A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Akeso